$2.685
-0.044 (-1.65%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
APUS Prediction & Forecast by Similar Chart Analysis
Alphio's APUS stock price prediction model matches the current Apimeds Pharmaceuticals US Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $2.71 (+1.09%). The 1-week path is $2.73 (+1.57%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy Apimeds Pharmaceuticals US Inc Stock?
Apimeds Pharmaceuticals US Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $2.68, and the company has reported a staggering net income loss of $35,059,852 in Q1 2026. Additionally, the RSI is at 26.149, indicating that the stock is oversold, but this does not suggest a buying opportunity given the ongoing financial instability.
APUS stock price ended at $2.68 on Friday, after losing -1.65%
Apimeds Pharmaceuticals US Inc (APUS) last closed at $2.6849999, losing -1.65%. These facts feed the 1-day and 1-week APUS price prediction above.
Forecast Drivers
Apimeds Pharmaceuticals US Inc (APUS) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bearish
Seasonality
Bullish
SMA 20
Bearish
SMA 200
Bearish
Similar Chart Patterns
Stocks whose recent price path most closely matches APUS, ranked by similarity.
Seasonality analysis for APUS
Historically the probability of a positive November return for APUS is 66.67%. April offers the highest probability of a positive month at 100.00%, while June is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
10-year price projections for APUS
| Month | Min Price | Avg Price | Max Price | Potential ROI |
|---|---|---|---|---|
| Nov 2026 | $1.80 | $2.14 | $2.61 | -20.40% |
| Dec 2026 | $1.92 | $1.96 | $2.05 | -26.94% |
In 2026, Apimeds Pharmaceuticals US Inc (APUS) is projected to range from $1.80 to $2.61.
Apimeds Pharmaceuticals US Inc 2026 monthly forecast
In Nov 2026, Apimeds Pharmaceuticals US Inc is projected to average $2.14, with a low of $1.80 and high of $2.61.
In Dec 2026, Apimeds Pharmaceuticals US Inc is projected to average $1.96, with a low of $1.92 and high of $2.05.
Related articles
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.